Indication
High Risk Superficial
1 clinical trial
1 product
Clinical trial
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder CancerStatus: Completed, Estimated PCD: 2022-02-24
Product
Bacillus Calmette-Guérin